Description: e-Therapeutics plc is a United Kingdom-based drug discovery and development company. The Company's discovery platform is based on the network of pharmacology and chemical biology. The Company operates in the business segment of drug discovery and development. The Company applies its platform to the discovery of new drug candidates. The therapeutic focus of the Company's discovery activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and antivirals. The Company generates a range of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule antiTNFα; ETS2400, in Hedgehog pathway inhibition, and ETS5200, which delivers a range of spectrum antivirals. The Company has completed a Phase IIb study of a drug candidate for depressive disorder, ETS6103, as well as Phase I clinical trials in cancer for ETS2101.
Home Page: www.etherapeutics.co.uk
ETX Technical Analysis
4 Kingdom Street
London,
W2 6BD
United Kingdom
Phone:
44 20 4551 8888
Officers
| Name | Title |
|---|---|
| Mr. Ahmad Ali Mortazavi | CEO & Director |
| Mr. Michael Anthony Bretherton ACA, B.A. | Acting Interim CFO & Director |
| Dr. Laura Roca-Alonso Ph.D. | Chief Operating & Bus. Officer |
| Mr. Alan Whitmore B.Sc., Ph.D. | Chief Scientific Officer |
| Ms. Sarah Clare | Director of Fin. & Compliance |
| Ms. Alison Gallafent | Chief Intellectual Property Officer |
| Mr. Ankit Sharma | Head of Software Engineering |
| Mr. Graham Craggs | Head of Therapeutic Discovery |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.0889 |
| Price-to-Sales TTM: | 441.8612 |
| IPO Date: | |
| Fiscal Year End: | January |
| Full Time Employees: | 39 |